Production (Stage)
ProQR Therapeutics N.V.
PRQR
$1.91
$0.126.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.58% | -68.03% | -43.42% | 66.70% | 13.22% |
| Total Depreciation and Amortization | -4.88% | -8.73% | 8.24% | 18.36% | 27.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.34% | 94.09% | 251.04% | -50.26% | 30.89% |
| Change in Net Operating Assets | 29.37% | -123.42% | 156.19% | -25.97% | -117.86% |
| Cash from Operations | -1.20% | -73.92% | 23.90% | 40.21% | -134.25% |
| Capital Expenditure | 70.34% | 78.12% | 14.80% | 10.19% | -444.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -147.04% | -- | -- | -- |
| Cash from Investing | 98.78% | -155.21% | 5,079.67% | 10.19% | -20,077.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.41% | 80.40% | -5.09% | 54.56% | -124.32% |
| Issuance of Common Stock | -58.64% | 35,921.61% | -99.34% | 200.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -15.67% | 6,576.87% | -62.85% | 56.64% | -63.75% |
| Foreign Exchange rate Adjustments | -744.23% | 431.44% | -248.13% | -92.87% | 143.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.40% | 3,751.83% | 231.53% | 36.04% | -176.04% |